More than a few companies that did well in the past are out of favor with investors. And that could spell opportunity.

Arcturus Therapeutics (ARCT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed ...

Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Unlike at the height of the pandemic, oral antiviral therapy Paxlovid is Pfizer's strongest COVID-19 product now instead of its Comirnaty vaccine. In the third quarter of 2024, Paxlovid raked in sales ...

Amid a share value slump and executive turmoil, Pfizer reported a robust quarter, thanks in part to Covid-19 drug sales.

Pfizer (PFE) stock fell even as the company beat forecasts with its Q3 results and increased its full-year outlook.Find out ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Pfizer raised its full-year profit forecast after better-than-expected sales of its COVID-19 treatment helped it beat Wall Street estimates for third-quarter earnings on Tuesday.